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ess: rdahl@as.aaa.dk.Summary Asthma is a complex disease of the respiratory tract associated with
chronic inflammation in which an intricate network of cells and cellular factors plays
a major role. Asthma is one of the most common chronic diseases, with an estimated
300 million cases worldwide, imposing a considerable burden on society in morbidity,
quality of life, and healthcare costs. Inhaled corticosteroids (ICSs) form the gold
standard, first-line therapy in the effective management of persistent asthma and
reduce morbidity and mortality from asthma. However, long-term use of high-dose
ICS therapy has potential to cause systemic side effects—impaired growth in
children, decreased bone mineral density, skin thinning and bruising, and cataracts.
Hypothalamic–pituitary–adrenal-axis suppression, measured by serum or urine
cortisol decrease, correlates with the occurrence of systemic side effects of high-
dose ICSs. Therefore, cortisol may be a relevant surrogate marker to identify the
potential for adverse effects from ICS therapy. Ciclesonide is a new generation ICS
with demonstrable safety and efficacy in the treatment of asthma. The unique
pharmacologic characteristics of ciclesonide, such as reduced local adverse effects,
lack of cortisol suppression, and the option for once-daily dosing, may improve
compliance with therapy and allow long-term use of ICSs without fear of systemic
adverse effects.
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Asthma is a complex disease that exhibits many
clinical phenotypes in both adults and children.1
The major characteristics of asthma include a
variable degree of airflow obstruction, bronchial
hyperresponsiveness, and airway inflammation.2
The chronic inflammation associated with asthma
involves an intricate network in which a number of
cells and cellular factors play a major role. The
presence of chronic inflammation in the airways
leads to an increase in recurrent episodes of
wheezing, breathlessness, chest tightness, and
coughing. These episodes are typically associated
with extensive but variable airflow obstruction that
may be reversible either spontaneously or with
treatment. Although asthma begins most often in
childhood and adolescence, it can develop at any
time in life. A cross-sectional analysis of a group of
patients with severe asthma indicated that there
exists a phenotypic difference between patients
with early onset and late-onset disease3; therefore,
differentiating asthma by age at onset and the
presence or absence of eosinophils may be bene-
ficial in identifying asthma phenotypes that could
benefit genetic and therapeutic studies.
Asthma is among the most common chronic
diseases in the world, and the incidence has
increased in the past 20 years, especially among
children. An estimation of worldwide asthma
prevalence suggests a trend of an increasing
number of cases in developed nations. However,
the lower incidence reported from developing or
underdeveloped countries may represent a lack of
awareness of the disease or the lack of well-
developed medical care.2,4 An estimated 300
million people worldwide currently suffer from
asthma, and an additional 4100 million persons
are likely to suffer from this disease by the year
2025.5 Asthma imposes a considerable burden on
society in morbidity, quality of life, and healthcare
costs.6 In the US, an estimated $9.4 billion was
spent on asthma-related direct costs, and the
indirect costs from lost work productivity
amounted to $4.6 billion, for a total of $14.0
billion in the year 2002.7 A substantial proportion of
family income, in a range of 5.5–14.5% in the US,has been attributed to the cost of medical treat-
ments for asthma, whereas the cost of asthma
treatment in India is 9% of per capita annual
income.5 Asthma is one of the leading causes for
hospital admission in children in the UK, with more
than 75,000 asthma-related emergency hospital
admissions each year. With approximately 4 million
asthma consultations and 1500 deaths from asthma
each year, asthma exhausts £2.5 billion in health-
care costs in the UK.5
A wide array of pharmacologic therapies have
been developed to prevent and control asthma
symptoms, reduce the frequency and severity of
asthma exacerbations, and reverse airflow obstruc-
tion.8 Quick-relief or reliever medications used for
asthma include short-acting b2-agonists, anticholi-
nergics, and systemic corticosteroids. Long-term
preventive or controller medications used to treat
asthma are corticosteroids, cromolyn sodium,
nedocromil, long-acting b2-agonists, methyl-
xanthines, leukotriene modifiers, and immunoglo-
bulin E antibody blocker (omalizumab).5,8,9
Glucocorticosteroids are the most potent and
consistently effective anti-inflammatory agents
for effective long-term management of asthma.
Inhaled corticosteroids (ICS) are the first-line
treatment of choice for persistent asthma. Clinical
studies have shown that ICS significantly reduce
airway hyperresponsiveness, effectively prevent
acute exacerbations, improve lung function, and
decrease symptom severity.10 The efficacy of ICS in
reducing airway inflammation and hyperresponsive-
ness has been the major factor behind the wide-
spread use of these agents as initial therapy in the
treatment of moderate to severe asthma.11,12 The
national and international guidelines for asthma
management currently recommend ICS as the first-
line therapy at low doses for mild persistent asthma
and as the preferred therapy at medium doses with
long-acting b2-agonists for moderate asthma.
2 High
doses of ICS are only recommended for patients in
whom persistent asthma is inadequately controlled
even after combined treatment with medium-dose
ICS and long-acting inhaled b2-agonists. However,
high-dose ICS use may be associated with systemic
side effects including osteoporosis, reduced growth
velocity in children, skin thinning, cataracts, and
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Table 1 Potential local and systemic side effects
of inhaled corticosteroids.
Local adverse
effects
Systemic side effects
Pharyngitis Suppressed HPA-axis function
Dysphonia Adrenal crisis (with
insufficiency)
Reflex cough Suppressed growth velocity in
children
Bronchospasm Decreased lower-leg length in
children
Oropharyngeal
candidiasis
Reduced bone mineral density
Suppressed HPA-axis function
Bone fractures
Osteoporosis
Skin thinning
Skin bruising
Cataracts
Glaucoma
HPA ¼ Hypothalamic–pituitary–adrenal.
Systemic side effects of inhaled corticosteroids 1309glaucoma.11,13,14 Local side effects are also com-
monly associated with ICS, including oropharyngeal
candidiasis, dysphonia, reflex cough, bronchos-
pasm, and pharyngitis.11,13 A summary of potential
side effects caused by ICS is shown in Table 1. The
objectives of this review are to discuss clinically
relevant and meaningful systemic side effects of
ICS, with an emphasis on the effect of long-term
adrenal suppression.Systemic side effects of inhaled
corticosteroids (ICS)
Although the prevalence of systemic side effects of
ICS is lower in comparison with systemic corticos-
teroids, high-dose ICS use has the potential to
cause systemic side effects. Systemic exposure of
ICS is directly related to the development of side
effects. The amount of an inhaled or nasal
corticosteroid that reaches the systemic circulation
is the sum of the drug that is available after
absorption across the lungs or nasal mucosa and
from the gastrointestinal tract. The fraction of the
drug that is deposited in the mouth will be
swallowed, and oral bioavailability is determined
by its absorption from the gastrointestinal tract and
the degree of first-pass metabolism in the liver.15
Because most of the drug deposited in the airways
will eventually also be absorbed into the systemic
circulation, pulmonary bioavailability also plays a
role in the potential of an ICS to cause systemiceffects. A reduction in the oropharyngeal deposi-
tion of ICS can be achieved by using a spacer device
with a metered-dose inhaler (MDI), by mouth
washing, or by using dry-powder inhalers,14 but
the presence of electrostatic charge on plastic
devices16 and the bulkiness of spacers are some of
the drawbacks that could contribute to decreased
compliance. Therefore, an ICS with durable, lung-
targeted activity and low systemic exposure would
have a theoretical advantage over currently avail-
able therapies for persistent asthma. In addition,
pharmacokinetic parameters such as high lung
deposition, high receptor binding, long pulmonary
retention, and high lipid conjugation would im-
prove or maintain the efficacy of such an ICS.17
Pharmacokinetic parameters such as rate of
systemic clearance, volume of distribution, half-
life, and accumulation also contribute to overall
systemic exposure. Concomitant use of other ICS
may play important causal roles in systemic side
effects by pharmacologic interaction or increased
total steroid load. The risks associated with
systemic ICS exposure have been extensively
studied and reviewed.11,13–15,18,19 These systemic
side effects, including osteoporosis, growth retar-
dation, posterior subcapsular cataract formation,
glaucoma, and skin thinning and bruising, are
thought to be related to hypothalamic–pituitary–a-
drenal (HPA)-axis suppression.14,19HPA-axis suppression
The most serious adverse effect of ICS use is
adrenal crisis after complete suppression of HPA-
axis function.15,20 Corticosteroids can exert HPA-
axis suppression by down-regulating corticotrophin
(adrenocorticotropic hormone) production by the
same feedback-inhibition loops that control endo-
genous glucocorticoid production, thus leading to
adrenal suppression.20 Although several studies
have suggested that adrenal insufficiency after ICS
therapy will rarely lead to acute adrenal crisis, a
recent survey from the UK suggests that the use of
ICS in excess of the currently recommended guide-
lines is associated with greater risk.21 This study
reported adrenal crisis in 33 patients (of 2912
questionnaires) who had received ICS
(500–2000 mg/day), of whom 91% received flutica-
sone propionate and 3% received fluticasone pro-
pionate and budesonide.
Several studies have investigated HPA-axis func-
tion after ICS therapy (Table 2).21–30 Although
study designs differ in that studies were either
uncontrolled, did not consider previous oral
corticosteroid therapy, were of inconsistent
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R. Dahl1312treatment duration, employed a variety of in-
haler types, or used different methods to assess
HPA-axis suppression, these studies demon-
strate that HPA-axis suppression occurs after high-
dose ICS therapy. Many studies performed in
healthy adults revealed HPA-axis suppression com-
pared with baseline.22,31 Some studies in asthmatic
patients with normal HPA-axis function have also
revealed dose-related cortisol suppression.24
Therefore, HPA-axis suppression exists in normal
individuals and asthmatic patients treated with
high-dose ICS, but the extent of HPA-axis suppres-
sion is likely dependent on the dose, duration, and
timing of corticosteroid administration.32 However,
several clinical studies have shown that cicleso-
nide, a nonhalogenated ICS,33 has no appreciable
effect on cortisol secretion. Short-term and long-
term studies with ciclesonide 160–640 mg/day in
the morning or evening did not suppress serum or
24-h urinary cortisol.27,34–36 Because ciclesonide
does not cause significant cortisol suppression, it is
unlikely that ciclesonide poses a risk for other
systemic side effects that are also thought to be
related to HPA-axis suppression, unlike other ICS
therapy.
To develop a dependable method for evaluating
systemic bioavailability, a recent study compared 6
ICS preparations.26 The authors concluded that a
comparison of ICS should be based on the effective
dose, rather than on the number of micrograms.
Further studies along these lines could be helpful in
assessing the therapeutic index of various ICS.
Outcomes from several studies suggest that low to
medium ICS doses may disturb basal cortisol
secretion in adults and children, although the
clinical relevance of this alteration is unclear.
Biochemical studies also suggest that high-dose
ICS may lead to adrenal suppression in children.37
Although the benefit of ICS clearly outweighs the
risk of therapy, use of ICS in children with earlyTable 3 Standard methods available to evaluate HPA-ax
Method Norma
Plasma cortisol level 0800 h
1600 h
2000 h
Urinary cortisol (24-h urine) Childr
Adole
Corticotrophin (ACTH) test An inc
Low-dose corticotrophin (ACTH) test An inc
Insulin-induced hypoglycemia Cortis
ACTH ¼ adrenocorticotropic hormone.
Adapted with permission from Salvatoni et al.38 (Table V on p. 35asthma onset is a particular concern because the
duration of therapy correlates with the extent of
adrenal suppression. Therefore, it is important to
titrate ICS dose to the effective dose because even
low to medium doses of ICS may perturb basal
cortisol level, a marker of adrenal suppression.
Finally, HPA-axis suppression may serve as a
sensitive and quantifiable surrogate marker for
potential systemic side effects of ICS.Measures of HPA-axis suppression
Many standardized methods that use static or
dynamic conditions are available for evaluating
HPA-axis suppression (Table 3).38 Static tests
measure cortisol levels in the morning, the circa-
dian rhythm of cortisol, and free urine cortisol
excretion. Dynamic tests measure the adrenal
response after the stimulation of the gland. The
corticotrophin adrenocorticotropic hormone test
evaluates the adrenal reserve, whereas insulin and
metyrapone tests evaluate the integrity of the
whole HPA-axis, both adrenal and pituitary.
Because plasma cortisol levels vary widely among
individuals, baseline levels for each patient ideally
should be obtained before starting ICS treatment.
To obtain consistent results, the morning cortisol
level determinations should be performed at the
same time and confirmed by repeated testing.39 A
careful evaluation of data is necessary to detect
any underlying clinical effects or HPA-axis suppres-
sion.14,40 In addition, measurement of 24-h urinary
free cortisol excretion has been proposed as a
better method for assessing basal cortisol levels in
a dose–response manner.19,25,26,41 However, similar
to morning serum cortisol measurement, urinary
free cortisol measurement may not be predictive of
clinical adrenal suppression. Because the technique
is noninvasive, it is primarily useful in determining
cortisol levels in children.13is suppression.
l range (mmol/L)
: 138–635
: 83–413
: p50% of 800 h
en: 5.5–74
scents:14–152
rease of 200 in plasma cortisol level or a level of 500
rease of 200 in plasma cortisol level or a level of 500
ol level X550
8).
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tion (between 8 and 9 AM) and short corticotrophin
(cosyntropin) stimulation tests have been the
standard tests for assessing basal cortisol secretion
and HPA-axis responsiveness, respectively,20 studies
suggest that these tests may not be sensitive
enough to detect low levels of HPA-axis suppression
caused by ICS.23 The standard 250-mg cosyntropin
test uses a supraphysiologic dose of cosyntropin and
may miss mild adrenal suppression. Therefore, low-
dose cosyntropin tests (with 0.5 mg/m2 cosyntropin)
are more physiologic and are therefore being
advocated.23 The low-dose cosyntropin test has
been thought to correlate well with the insulin-
induced hypoglycemia test, which is still widely
considered in the definitive study of HPA-axis
integrity. However, compared with the insulin-
induced hypoglycemia test, the low-dose cosyntro-
pin test has shown fewer false-negative results.42
Because the test is relatively new, some investiga-
tors have suggested that if the results of this test
are not definitive, it should be followed by an
insulin-induced hypoglycemia or metapyrone
test.20 It is noteworthy that, compared with other
HPA-axis function measures, both insulin-induced
hypoglycemia or the metapyrone test are techni-
cally difficult, require hospitalization, and are
more hazardous and expensive than cortisol mon-
itoring.
Because of the availability of a variety of
laboratory tests for the evaluation of cortisol, it is
important to use a sensitive and feasible method
that could be adopted in a clinical laboratory.
Adopting such a practice in the clinic could help
optimize ICS use, thus increasing efficacy and
safety of ICS in the management of asthma.Growth suppression
Because ICS treatment is currently recommended
for children of all ages with persistent asthma, the
potential effect of ICS on children’s growth is a
crucial consideration. Severe asthma or concomi-
tant atopy may negatively affect growth in chil-
dren.8,11 ICSs to treat asthma are likely to be a
long-term therapy, especially in children,43 and
long-term use of ICS in children may potentially
lead to adverse effects on growth by suppression of
HPA-axis function. However, because several other
factors contribute to normal growth, including
genetic background and individual variations in
onset of puberty, it is difficult to assess the effect
of ICS on growth in children with asthma.
Growth has been commonly evaluated using
knemometry to measure changes in lower leglength as an index of short-term growth, usually
over a 2–4-week period. A decrease in short-term
lower-leg growth velocity demonstrates the sys-
temic activity of ICS. In a double-blind, rando-
mized, 2-week crossover trial in 17 asthmatic
children, knemometry and other markers of growth
indicated greater growth suppression by beclo-
methasone dipropionate (BDP) than by fluticasone
propionate.44 In another study, no significant
difference in the lower-leg growth rate was found
between budesonide and fluticasone propionate at
high doses (400 mg/day).45 Finally, both fluticasone
propionate and budesonide caused a significant
slowing of lower-leg growth length compared with
placebo in asthmatic children ages 1–3 years.46 In
contrast, ciclesonide 40–160 mg/day showed no
effect on the short-term lower-leg growth rate
among 24 children (age 6–12 years) with asthma.47
Long-term studies of duration greater than 12
months suggest that asthmatic children treated
with ICS for this duration ultimately achieve near-
normal adult final heights. The Childhood Asthma
Management Program (CAMP) study compared the
long-term effects of therapy of inhaled budesonide
(400 mg/day), nedocromil (16mg/day), or placebo.
Children treated with budesonide grew at a slower
rate during the first year compared with those
treated with nedocromil or placebo; however,
there was no difference in growth velocity in
subsequent years.48 A long-term cohort study
demonstrated no difference in attained adult
height between age- and sex-matched children
with asthma who were either treated or not
treated with ICS. In addition, there was no
difference in attained height between asthmatic
and nonasthmatic children.49 These results were
confirmed by a study50 comparing adult height
attained by asthmatic patients treated with bude-
sonide (412 mg mean daily dose for 9.2 years),
asthmatic children who were never treated with
ICS, and a small group of healthy, nonasthmatic
siblings. There was no apparent difference in adult
height among the study groups. Taken together, the
long-term studies suggest that, overall, asthmatic
children treated with ICS attain near-normal adult
height,18 although individual variations could still
exist.51Bone density and osteoporosis
Glucocorticoids reduce bone formation and in-
crease bone resorption by direct actions on
osteoblasts and osteoclasts. These phenomena
can lead to bone calcium loss via urine and
decreased vitamin D-mediated calcium absorption
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stores. Therefore, ICS therapy during childhood, a
critical time for bone development, could ad-
versely affect bone mass and may predispose
asthmatic children for osteoporosis during adult-
hood.37,52 Several studies have measured bone
mineral density (BMD) in growing children who
have asthma to determine the effects of ICS on
BMD; however, the results are difficult to interpret
because of the expected constant change in BMD
throughout childhood. A study of 48 asthmatic
prepubertal children treated with either BDP or
budesonide indicated a reduction in BMD.52 How-
ever, a study of 15 asthmatic children treated with
BDP (200–450 mg/day) for 4–60 months revealed
BMD equivalent to that of the control subjects.53 In
children with moderate to severe asthma (age
range, 5–10 years; mean age, 6.7 years) treated
with 200 mg/day of fluticasone propionate or
400 mg/day BDP for 82 weeks, neither BDP or
fluticasone propionate had an effect on BMD.54
Finally, the CAMP study indicated no difference in
BMD for budesonide therapy compared with nedo-
cromil or placebo therapies.48 Such studies suggest
that ICS therapy at low to moderate doses is not
associated with a reduction in BMD in children.
However, prolonged HPA-axis suppression and any
effect on bone metabolism in children administered
high-dose ICS remain to be examined.
Several studies have investigated the effects of
ICS on BMD in adults with asthma. A cross-sectional
study of 1673 adults (age range, 56–91 years)
suggested that women receiving ICS therapy had
modest decreases in BMD at the ultradistal radius,
hip, and spine compared with women who received
no ICS treatment or women receiving oral corticos-
teroids. However, there was no significant differ-
ence in BMD between untreated men and men
treated with oral corticosteroids or ICS.55 The
results of two studies in patients ages 18–50 years
treated with mometasone furoate 200 or 440 mg
twice daily for 2 years were mixed, with the lower-
dose study demonstrating significant reductions in
lumbar spine BMD, whereas the higher-dose study
reported no statistically significant difference in
lumbar spine BMD versus placebo.56 Treatment of
19 nonsmoking asthmatic women (age range, 40–63
years; mean age, 53 years) and 19 similar-age
healthy, nonsmoking women with BDP (1000 mg/
daily) for 1 year resulted in no significant changes in
BMD.57 Conversely, bone-mass studies in three
groups of adults with asthma indicated that BMD
was significantly lower in groups receiving ICS
therapy (BDP; 1000–2000 mg/day for 1 year) or ICS
and low-dose prednisolone therapy compared with
BMD in asthmatic patients who had never receivedICS or systemic corticosteroids.58 This study sug-
gested that asthmatic patients treated with high-
dose inhaled BDP and intermittent systemic corti-
costeroids experienced a reduction in vertebral
bone density. Notably, the degree of bone loss was
similar in patients treated with ICS therapy alone
and in patients treated with continuous low-dose
systemic corticosteroids. A cross-sectional study of
196 adult asthma patients (age range, 20–40 years)
with a mean duration of 6 years (range, 0.5–24
years) of ICS treatment indicated a negative
relationship between cumulative ICS dose and
BMD of the lumbar spine and femoral neck.59 This
study also indicated that doubling the dose of ICS
resulted in a decrease in lower-spine BMD (0.16
standard deviation). BMD of a patient receiving ICS
treatment of 2000 mg/day for 7 years will have BMD
that is 1 standard deviation lower than that of a
patient on 200 mg/day for 1 year, indicating that a
higher ICS dose could double the risk of fracture.
Therefore, long-term ICS use results in BMD reduc-
tions that could lead to increases in fractures in
adults.Cataracts and glaucoma
Although the use of systemic corticosteroids poses
an increased risk for cataracts, it has been difficult
to establish a definitive link between ICS therapy
and cataract formation. The occurrence of poster-
ior subcapsular cataracts with ICS and oral steroid
therapy was studied in a cross-sectional survey.60
The results indicated that 27% of the 48 adult
patients had subcapsular cataracts. The increased
incidence correlated with the daily dose and
duration of oral prednisolone but was not asso-
ciated with the dose or duration of ICS use.
However, in a population-based, cross-sectional
study of 3654 older adult patients (age range,
49–97 years) in Australia, there was an association
between ICS use and posterior subcapsular and
nuclear cataracts.61 The CAMP research group also
studied the development of posterior subcapsular
cataracts associated with long-term budesonide,
and only 1 child developed evidence of cataract at
the end of the 6-year study period.48 Therefore,
the risk of subcapsular and nuclear cataract
development related to ICS use seems minimal in
asthmatic children, although the risk may be
greater in older patients. Therefore, no firm link
between cataract formation and ICS use has been
made to date, and longer follow-up regarding this
important potential adverse effect seems war-
ranted.
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therapy include only a few isolated case reports. A
prospective study of 187 patients with various
pulmonary conditions and no documented history
of glaucoma evaluated the risk of elevation of
intraocular pressure in patients after the initiation
of ICS therapy.62 The results indicated no significant
increase in intraocular pressure in these patients;
hence, they suggest that the risk of glaucoma after
ICS therapy is very low. Garbe et al.63 conducted a
case-control study involving more than 40,000
patients to investigate the association of ICS
therapy with increased risk of ocular hypertension
or open-angle glaucoma. Therapy with ICS was not
associated with increased risk of either. However,
the authors suggested that long-term ICS use may
increase the risk and that monitoring of ocular
pressure may be necessary in patients on prolonged
ICS therapy. Published results concluded that the
risk of glaucoma following ICS therapy is most likely
small, and future studies might be helpful in
defining a definitive link between ICS use and
glaucoma in the elderly.Skin thinning and bruising
Several studies indicate that skin thinning and skin
bruising, common adverse effects of long-term oral
corticosteroid use, can be linked to ICS therapy. A
cross-sectional study of 68 patients treated for
chest diseases showed that patients treated with
high-dose ICS had significantly thinner skin (15–19%
thinner compared with controls).64 The prevalence
of easy bruising in patients treated with ICS in a
respiratory clinic and in a control group without ICS
therapy was studied in 406 patients.65 The results
suggested that ICS therapy, especially with high
doses, increased the risk of easy bruising. Although
sex was indicated to be a factor in this study
because women reported easy bruising at a higher
frequency versus men, men treated with ICS also
had a higher relative risk for bruising than women.
A Finnish study of asthmatic patients suggested
that inhaled budesonide decreases skin collagen
synthesis within a short period of time (6 weeks).66
Roy et al.67 studied the prevalence of skin bruising
in relation to adrenocortical function and ICS
therapy in 100 asthmatic patients. Adrenocortical
function tests indicated that a minority of patients
had lower urinary or blood cortisol levels, which
was evident in patients with skin bruising. In
addition, the likelihood of skin bruising was
common in women receiving ICS therapy for
asthma, with an increased occurrence of skin
bruising in older women with asthma. On the basisof these studies, it appears that there is an
increased rate of skin thinning and bruising in
patients treated with ICS. The overall risk is likely
related to dose, duration of use, and sex.Summary
Concerns regarding potential systemic side effects
may limit the use of ICS doses that are effective for
long-term asthma management. Therefore, an ICS
with high efficacy and low systemic bioavailability
may ultimately result in fewer systemic side effects
and would be desirable. ICSs can reach systemic
circulation either by deposition in the oropharynx,
where they are swallowed and absorbed into the
systemic circulation from the gastrointestinal
tract, or by deposition in pulmonary airways.
Therefore, an ICS with efficacy comparable with
the existing gold standard and a low risk for
systemic effects may reduce concerns about sys-
temic side effects and improve compliance with—
and thus efficacy of—ICS maintenance therapy.
Ciclesonide, a nonhalogenated ICS, possesses key
pharmacokinetic and pharmacodynamic character-
istics that yield high efficacy and low risk for
systemic exposure. Because ciclesonide does not
cause significant cortisol suppression, it is unlikely
that ciclesonide poses a risk for other systemic side
effects that are thought to be related to HPA-axis
suppression. However, no data for ciclesonide are
available for other systemic side effects such as
skin thinning, bruising, and fracture, and studies
are necessary to further investigate long-term
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